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AbsTrACT
Objectives We sought to confirm in very early 
rheumatoid arthritis (era) a much greater superiority 
(30%) of first- line etanercept+methotrexate (eTn+MTX) 
over treat- to- target MTX (MTX- TT) than previously 
reported in era (14%); and explore whether eTn 
following initial MTX secures a comparable response to 
first- line eTn+MTX.
Methods Pragmatic, open- label, randomised controlled 
trial of treatment- naïve era (≤12 months symptom), 
Disease activity score 28 joint (Das28)- erythrocyte 
sedimentation rate (esr) ≥3.2, rheumatoid factor 
(rF)+/−anticitrullinated peptide antibody (acPa) positive 
or ultrasound power Doppler (PD) if rF and acPa 
negative. subjects were randomised 1:1 to eTn+MTX; 
or MTX- TT, escalated to eTn if week 24 Das28- esr 
≥2.6 and intramuscular corticosteroid at protocolised 
time points. Primary endpoint of week 48 Das28esr 
remission with clinical and imaging secondary endpoints.
results We randomised 120 patients, 60 to each arm 
(71% female, 73% rF/84% acPa positive, median (iQr) 
symptom duration 20.3 (13.1, 30.8) weeks; mean (sD) 
Das28 5.1 (1.1)). remission rates with eTn+MTX and 
MTX- TT, respectively, were 38% vs 33% at week 24; 
52% vs 38% at week 48 (ors 1.6, 95% ci 0.8 to 3.5, 
p=0.211). Greater, sustained Das28- esr remission 
observed with eTn+MTX versus MTX- TT (42% and 
27%, respectively; p=0.035). PD was fully suppressed by 
week 48 in over 90% in each arm. Planned exploratory 
analysis revealed or 2.84, 95% ci 0.8 to 9.6) of 
achieving remission after 24 weeks of eTn administered 
first line compared with administered post- MTX.
Conclusions compared with remission rates 
typically reported with first- line tumour necrosis factor 
inhabitor+MTX versus MTX- TT, we did not demonstrate 
a larger effect in very era. neither strategy conferred 
remission in the majority of patients although ultrasound 
confirmed local inflammation suppression. Poorer eTn 
response following failure of MTX- TT is also suggested.
Trial registration number
ncT02433184
InTrOduCTIOn
Biological disease- modifying antirheumatic drugs 
(bDMARDs) are established in the treatment of 
rheumatoid arthritis (RA) but failure of conventional 
synthetic DMARD (csDMARD), usually metho-
trexate (MTX), is a minimum hurdle requirement.1 
Key messages
What is already known about this subject?
 ► In new onset, early rheumatoid arthritis (ERA), 
biological disease- modifying antirheumatic drug 
(bDMARD) (with mainly tumour necrosis factor 
inhibitor (TNFi) tested)+methotrexate (MTX) 
has not been shown to be superior to MTX+/−
additional conventional synthetic DMARD in 
strategy trials to justify first- line use; although 
studies to date have not necessarily included 
all the elements of optimal treat- to- target (TT) 
strategies. Randomised controlled trial data of 
targeted synthetic DMARDs (janus kinase (JAK) 
inhibitors in MTX and bDMARD- inadequate 
response (IR)), suggest similar pragmatic 
evaluation is needed to inform on its place.
What does this study add?
 ► This study did not confirm a large effect size (of 
30%) suggested in previous exploratory analysis 
with first- line TNFi+MTX compared with MTX- 
TT. This highlights that despite incorporating all 
the recommended TT strategies in a real- life, 
treatment- naïve, early(≤12 months symptom) 
RA cohort, a ceiling effect with both first- line 
MTX- TT and etanercept- TNFi+MTX exists; that 
does not appear attributable to ongoing local 
inflammation (as evidenced by power Doppler 
ultrasound).
 ► The data suggest that in a very ERA MTX- TT- IR 
cohort (compared with longer- duration cohort 
of previous pivotal MTX- IR trials), a proportion 
still may not respond to TNFi; implying 
preceding inflammation and drug exposure 
may lead to an acquired biology of less TNFi 
responsiveness.
How might this impact on clinical practice or 
future developments?
 ► There is a continued need to understand 
the basis for this limited response rate and 
testing of alternative strategies to ensure more 
complete remission rates are achieved.
 ► The exploratory observations support research 
to understand the biology of a very ERA 
MTX- TT- IR subgroup for future therapeutic 
opportunities acknowledgements.
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Early arthritis
Extensive evaluation of first- line csDMARD and bDMARD, 
mainly tumour necrosis factor inhibitor (TNFi),2 including 
pragmatic strategic studies in DMARD- naïve and MTX- naïve 
cohorts have been contradictory in demonstrating clear benefit 
of bDMARD.3–7 Therefore, bDMARDs are still restricted to 
MTX- inadequate response (IR), which avoids overtreatment.8 
Nevertheless, with first- line bDMARD combination, remission 
is achieved earlier,9 10 with benefits for quality of life and jobs,11 
and greater possibility of bDMARD tapering.12 Exploratory 
analysis in a previous study suggested a heightened difference in 
remission rate (of 30%) with first- line bDMARD compared with 
MTX in very early RA (ERA).13 None of the treatment strategies 
achieve remission in the majority and remission rates are virtu-
ally always higher when drug is used first- line.14
The Very early Etanercept and MTX versus MTX with 
Delayed Etanercept in RA (VEDERA) study aimed, in a real- life 
cohort with treat- to- target (TT) strategies, to determine whether 
initial etanercept (ETN) and MTX compared with MTX- TT, 
conferred a larger than standard effect (30%) in very ERA and 
to explore the performance of ETN when administered first- line 
or following MTX.
PATIEnT And METHOds
VEDERA was a pragmatic investigator- initiated study conducted 
at Leeds Teaching Hospitals NHS Trust rheumatology outpatient 
department (full protocol details published15). All patients gave 
their written, informed consent to take part. Independent lay indi-
vidual from our public and patient advocacy group provided input 
into study design.
Patients
Eligible patients were ≥18 years, had new- onset ERA fulfilling 
2010 American College of Rheumatology/European League 
against Rheumatism (ACR/EULAR) RA classification criteria16; no 
prior DMARD therapy; ≤12 months symptom duration; disease 
activity score 28 joint (DAS28)- erythrocyte sedimentation rate 
(ESR) ≥3.2 with clinical evidence of synovitis; positive anticitrul-
linated peptide antibody (ACPA) and/or rheumatoid factor (RF), 
or if RF and/or ACPA negative, evidence on hand ultrasound (US) 
of power Doppler (PD) defined as grade ≥1 in at least one joint.
study design
VEDERA is a single- centre, phase IV, open- label, two- arm, 
randomised controlled trial in patients with ERA. Patients were 
block randomised 1:1 to first- line ETN+MTX or first- line 
MTX- TT for a total duration of 48 weeks.
ETN+MTX regimen: intramuscular (IM) depomedrone 
120 mg, subcutaneous ETN 50 mg weekly and oral MTX 15 mg 
weekly, increased to 20 mg and 25 mg weekly at weeks 4 and 
8, respectively. MTX- TT protocol: IM depomedrone and oral 
MTX monotherapy 15 mg weekly, increased to 25 mg weekly at 
2 weeks. If not in low disease activity (LDA) (DAS28- ESR ≤3.2) 
weeks 8, 12, 16 or 20, oral sulfasalazine (SSZ) 1 g two times per 
day and hydroxychloroquine (HCQ) 200 mg daily were added 
to MTX. At week 24, if DAS28- ESR ≥2.6, ETN was added to 
MTX (MTX- TTb), and SSZ and HCQ were discontinued. IM 
depomedrone 120 mg was administered in both arms at week 
12 if DAS28- ESR ≥3.2, weeks 24 and 36 if DAS28- ESR ≥2.6. 
Subcutaneous MTX was administered with intolerance to oral 
MTX. All patients received folic acid 5 mg each day (except day 
of MTX). Stable doses of oral glucocorticoids (≤10 mg/day of 
prednisone or equivalent) and/or a single non- steroidal anti- 
inflammatory drug were permitted.
All patients on ETN at week 48, stopped the ETN. Patients 
were treated as per standard practice with 48- week observational 
follow- up and established on bDMARD if they fulfilled National 
Institute for Health and Care Excellence (NICE) criteria (DAS28 
>5.1)17 (with ETN prescribed unless already tried and failed 
during the trial).
blinding
Trained research nurses blinded to allocation performed assess-
ments throughout the study. US assessments were performed by 
an ultrasonographer blinded to allocation.
Outcomes and assessments
The primary endpoint was the proportion who at week 48 achieved 
DAS28- ESR remission (DAS28- ESR ≤0.6). Multiple secondary 
endpoints: proportion achieving at weeks 12, 24, 48 and 96 
(only to be inferentially compared at week 96): DAS44 remission, 
DAS28 remission,18 Simplified Disease Activity Index (SDAI), Clin-
ical Disease Activity Index (CDAI),19 ACR and EULAR response20 
Boolean remission rates21; time to sustained remission (SR; defined 
as DAS28- ESR (or DAS44, SDAI, CDAI) remission observed at 
≥2 consecutive visits within weeks 12, 24, 36 and 48); change 
from baseline in Health Assessment Questionnaire Disability Index 
(HAQ)22 and normalisation of HAQ (to <0.5); change from base-
line in Visual Analogue Scales (VASs) for patient pain, and patient 
and physician global assessments of disease activity, EuroQoL-5 
Dimensions-3 Level23 and Rheumatoid Arthritis Quality of Life24; 
cumulative steroid dose. High- resolution US of dominant hand 
MCPs 1–5/wrists (or hand with greater evidence of inflammation) 
at weeks 0, 12, 24 and 48 to assess for synovitis, using semiquan-
titative (0–3) scores of Grey Scale (GS) and PD, and for presence 
of erosions.25 One of two assessors scanned the participants, with 
a third scanning <10%. Plain radiology of hands and feet to deter-
mine change in total van der Heijde modified Sharp score26 at 
weeks 48 and 96. The mean of scores by two independent readers 
who knew the order of the films but were blind to allocation 
was used and any significant disagreement adjudicated by a third 
reader. Finally, change in MRI synovitis score at 12, 24, 48 and 96 
weeks (to be reported separately).
safety
Adverse events (AE) and serious AE (SAE) were recorded during 
the 48- week protocolised treatment strategies.
statistical analysis
Sample size and power calculation
The Comparison of methotrexate monotherapy with a combi-
nation of methotrexate and etanercept in active, early, moderate 
to severe rheumatoid arthritis (COMET) studyubgroup remis-
sion rates of patients with ≤4 months since diagnosis treated 
with ETN+MTX or MTX monotherapy were 70% vs 35%, 
respectively.13 We expected remission rates in VEDERA patients, 
recruited at <12 months symptom onset rather than diag-
nosis, would be similar to the COMET very ERA subgroup (of 
less than 4 months since diagnosis). Therefore, remission rate 
in ETN+MTX was anticipated at 70% and 40% in MTX- TT 
(delayed or deferred ETN); at 1- beta=0.8, alpha=0.05 and 
accounting for 10% drop- out, 49 patients per arm were required, 
increased to 60 per arm to allow for an exploratory subgroup 
analysis of ETN+MTX compared with MTX- TTa (csDMARD 
throughout) and MTX- TTb (delayed ETN). We estimated that 
50% of MTX- TT patients would require delayed ETN.
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Figure 1 CONSORT flow diagram participant flow diagram up to week 96. CONSORT, Consolidated Standards of Reporting Trials.
Analysis
Complete plan can be found in the online supplementary 
material.
The full analysis set (intention to treat (ITT)), for efficacy 
and safety, included all patients randomised, as randomised, 
with per protocol (PP) set comprising all ITT patients with 
primary endpoint data available and no major protocol 
violations. Two- sided tests were conducted throughout at 
the 5% level of significance. The Holm correction (modi-
fied Bonferroni) to control for multiple comparisons of 
secondary outcomes set the critical p value for testing signif-
icance at the 5% level to p<0.00088.
Primary outcome
The primary analysis compared the proportions achieving 
DAS28ESR <2.6 between the ETN+MTX and MTX- TT arms 
using Pearson’s χ2 test. The ORs and 95% CI for the odds of 
achieving DAS28- ESR remission is reported. A number of 
planned sensitivity analyses of the primary outcome were 
conducted (detailed in results).
Secondary outcomes
Proportions achieving remission, ACR or EULAR response at 
96 weeks were compared between groups using Pearson’s χ2 
tests (with descriptive evaluation for the other time points). 
Changes in continuous variables were analysed using linear 
multilevel modelling. Baseline values were included as covari-
ates. An exponential autoregressive within- subject covariance 
pattern was found to be optimal using Akaike information 
criterion values after inspection of correlations between 
repeated observations. Severely skewed US and radiographic 
variables were analysed using quantile regression. Time to SR 
(as defined in ‘outcomes and assessment’) was analysed using 
log- rank tests.
Additional planned analyses
The response in ETN+MTX over the first 24 weeks was 
compared with the response in MTX- TTb (delayed ETN) over 
weeks 24–48. Proportions requiring escalation to triple therapy 
and bDMARD have been presented, as has cumulative IM 
steroid dose up to week 48.
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Table 1 Baseline demographics and disease profile for the entire 
group, ETN+MTX and MTX- TT
Variable All ETn+MTX MTX- TT
demographics
Age, years Mean (SD) 50.0 (12.8) 49.6 (12.5) 50.3 (13.2)
Female % (n/N) 71 (85) 65 (39) 77 (46)
rA presenting history, % (n/N) (unless otherwise stated)
Symptom duration, weeks, 
median (Q1, Q3)
20.3 (13.1 to 30.8) 19.2 (12.5 to 28.1) 20.8 (15.9 to 31.9)
Previous IM steroid 1 (1/120) 0 (0/60) 2 (1/60)
Previous IA steroid 0 (0/120) 0 (0/60) 0 (0/60)
Concomitant oral steroid 3 (3/120) 0 (0/60) 5 (3/60)
Concomitant NSAID 88 (105/120) 92 (55/60) 83 (50/60)
rA disease phenotype, % (n/N)
RF positive 73 (87/120) 70 (42/60) 75 (45/60)
ACPA positive 84 (101/120) 82 (49/60) 87 (52/60)
ANA positive 15 (18/120) 18 (11/60) 12 (7/60)
rA disease activity components, Median (Q1, Q3) (unless otherwise stated)
TJC28 11.0 (7.0, 17.0) 11.5 (6.0, 20.0) 10.0 (7.0, 16.0)
SJC28 5.0 (2.0, 9.0) 5.0 (3.0, 10.5) 5.0 (2.0, 9.0)
ESR, mm/hour 31.5 (18.5 to 51.0) 30.5 (17.0 to 51.5) 32.5 (20.5 to 51.0)
CRP, mg/L 8.8 (2.3, 24.0) 10.2 (1.8, 28.0) 8.0 (2.7, 21.5)
Disease activity VAS, mm 
Mean (SD)
57.1 (22.3) 60.7 (21.6) 53.6 (22.6)
rA disease activity scores, Mean (SD)
DAS28- ESR 5.7 (1.1) 5.8 (1.1) 5.6 (1.0)
DAS44- ESR 3.7 (0.8) 3.7 (0.9) 3.7 (0.7)
DAS28- CRP 5.1 (1.2) 5.2 (1.2) 4.9 (1.1)
DAS44- CRP 3.4 (0.8) 3.5 (0.9) 3.3 (0.8)
SDAI 31.6 (13.7) 34.2 (14.7) 29.0 (12.3)
CDAI 29.8 (12.7) 32.2 (13.6) 27.3 (11.2)
Patient- reported outcome measures, Mean (SD) (unless otherwise stated)
Global pain VAS, mm 53.5 (24.5) 59.0 (23.4) 48.1 (24.6)
HAQ- DI 1.2 (0.5) 1.2 (0.5) 1.1 (0.5)
RAQoL 17.3 (7.3) 16.8 (7.4) 17.9 (7.2)
In paid work % (n/N) 73 (88/120) 82 (49/60) 65 (39/60)
EQ- 5D- 3L index 0.5 (0.3) 0.4 (0.3) 0.5 (0.3)
RAWIS 18.2 (6.6) 19.0 (6.7) 17.3 (6.4)
ultrasound scores Median (Q1, Q3)
Total GS score 2.0 (0.0, 5.0) 3.0 (0.5, 5.0) 2.0 (0.0, 5.0)
Total PD score 0.0 (0.0, 2.5) 0.0 (0.0, 3.0) 0.0 (0.0, 2.0)
Total erosion score 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
radiographic score median (Q1, Q3)
Total modified Sharp score 2.5 (0.5, 6.0) 2.0 (0.5, 5.0) 2.5 (0.5, 6.3)
ACPA, anticitrullinated protein antibody; ANA, antinuclear antibody; CDAI, Clinical Disease Activity 
Index; CRP, C reactive protein; DAS28, Disease Activity Score 28 joint; EQ- 5D- 3L, EuroQoL-5 
Dimensions-3 Level; ESR, erythrocyte sedimentation rate; ETN, etanercept; GS, Grey Scale; HAQ- 
DI, Health Assessment Questionnaire Disability Index; IA, intra- articular; IM, intramuscular; MTX, 
methotrexate; NSAID, non- steroidal anti- inflammatory drug; PD, power Doppler; RA, rheumatoid 
arthritis; RAQoL, Rheumatoid Arthritis Quality of life Questionnaire; RAWIS, Rheumatoid Arthritis Work 
Instability Scale; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; 
TJC, tender joint count; TT, treat- to- target; VAS, Visual Analogue Scale.
Figure 2 (A) DAS28- ESR remission rates in ETN+MTX (n=60) and 
MTX- TT (n=60). Percentage patient estimated via multiple imputation. 
(B) Individual DAS28- ESR scores over time in ETN+MTX (n=60) and 
MTX- TT (n=60). DAS28, Disease Activity Score 28 joint; ESR, erythrocyte 
sedimentation rate; ETN, etanercept; MTX, methotrexate; TT, treat- to- 
target.
Additional unplanned remission analyses
The ACR/EULAR remission criteria27 were ‘provisional’ in 
2011; hence not included as an outcome of the trial. Neverthe-
less, additional, unplanned, descriptive data comparing ACR/
EULAR remission between groups at week 48 are presented.
The online supplementary file details handling of missing data.
rEsulTs
Patient disposition
Of 177 patients screened between October 2011 and October 
2015, 120 patients were recruited and randomly assigned to 
receive ETN+MTX (n=60) or MTX- TT strategy (n=60) (see 
online supplementary table S1). One hundred and four (87%) 
subjects reached week 48 and 98 (82%) week 96 (figure 1). 
Reasons for exclusion from PP efficacy set, withdrawals, inclu-
sion and exclusion criteria for all screened patients are included 
in the online supplementary table S1.
baseline demographics and characteristics
Patient demographics and baseline characteristics (table 1) were 
comparable between the two arms, and were representative of 
a new- onset, treatment- naïve, high disease activity ERA popu-
lation. Seventy- two per cent (81/113) had evidence of erosive 
disease (any Sharp erosion score >0). Only four patients had 
any prior steroid exposure reflecting a treatment- naïve inception 
cohort.
Primary endpoint
Of the full analysis set, 52% ETN+MTX vs 38% MTX- TT 
achieved DAS28- ESR remission at week 48 (OR 1.73, 95% CI 
0.81 to 3.70) p=0.160) (figure 2A; online supplementary table 
S2). Sensitivity analyses supported this main analysis, except 
when assuming that those with missing data treated with 
ETN+MTX responded while those receiving MTX- TT did not 
(see online supplementary table S3). Only under this assumption 
did we observe the disproportionately large difference (30%; 
63% ETN+MTX vs 33% MTX- TT) expected.
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Figure 3 Proportion of patients achieving DAS28- ESR remission 
following 24 weeks ETN exposure, either received first- line (ETN+MTX) 
or following failure to achieve remission on MTX- TT (MTX- TTb). 
Percentage patient estimated via multiple imputation. DAS, Disease 
Activity Score 28 joint; ESR, erythrocyte sedimentation rate; ETN, 
etanercept; MTX, methotrexate; TT, treat- to- target.
secondary endpoints
Clinical outcomes
DAS remission rates
Thirty- nine per cent receiving ETN+MTX achieved remission 
at week 12 vs 17% receiving MTX- TT (OR 3.18, 95% CI 1.35 
to 7.50); figure 1B). By week 24, the groups were similar (see 
online supplementary table S2). Between- group differences 
in alternative DAS- based remission criteria were descriptively 
similar to DAS28- ESR remission (see online supplementary 
tables S4–S6). At week 96, there were no statistically significant 
differences between the groups in remission rates; continuous 
DAS scores (unplanned descriptive analysis) were similar across 
arms (see online supplementary table S7).
Boolean remission and DAS28ESR LDA rates (unplanned analysis)
Differences in the proportions achieving ACR/EULAR Boolean 
remission and DAS28ESR LDA were consistent with those 
reported for DAS28ESR remission (see online supplementary 
tables S8–S9).
Sustained remission
Sustained (DAS28- ESR) remission was achieved earlier in 
the ETN+MTX group compared with MTX- TT (after 24 vs 
36 weeks, in 42% vs 27%, respectively, p=0.035); but at the 
corrected significance threshold (p<0.0008) this was not statis-
tically significant (see online supplementary table S10).
EULAR and ACR response rates
ETN+MTX arm achieved earlier EULAR and ACR responses 
compared with MTX- TT; but response rates were comparable 
by week 48, maintained at week 96 (see online supplementary 
tables S11–S15).
Planned exploratory analysis of early and delayed ETN + MTX
At week 24, 29 patients in MTX- TT arm had not achieved 
DAS28- ESR remission, and switched to ETN+MTX. One 
received only one dose of ETN and was excluded from subgroup 
analysis. Response to 24 weeks duration ETN+MTX exposure 
if received early (ETN+MTX) versus delayed (MTX- TTb), (with 
resetting of ‘baseline’ DAS28 in MTX- TTb to week 24) revealed 
an adjusted OR (95% CI) of achieving DAS28- ESR remission of 
2.84 (0.84 to 9.60) (figure 3).
MTX- TTb (delayed ETN) was on average, in a moderate 
disease activity state at week 48 (mean (SD) DAS28- ESR (3.21 
(1.12)). MTX- TTa (csDMARD throughout) maintained remis-
sion state at week 48 (2.58 (0.97)) (see online supplementary 
figure S1).
Patient-reported outcome measures
Tests of differences across the course of the trial revealed no 
statistically significant differences in functional improvement 
(figure 4A; online supplementary tables S16–S17), overall 
quality of life (see online supplementary table S18); patient VAS 
(figure 4B,C; online supplementary tables S19–S20), disease- 
specific quality of life (figure 4D; online supplementary table 
S21) or work instability (see online supplementary table S22).
Imaging outcomes
There were no statistically significant differences in total mTSS 
scores between the treatment arms at weeks 48 and 96, with 
minimal changes on average in both groups (see online supple-
mentary table S23 and figure S2).
US GS and PD scores decreased at week 12 in both arms, with 
no notable differences (table 2; online supplementary figures 
S3–S4). Comparable proportions in each arm had GS >0 and 
PD >0 at each time point. Over 50% in each arm scored GS >0 
from baseline to week 48. In contrast, the proportion with PD 
>0 diminished rapidly by week 12%–15% in each arm, main-
tained to week 48 (table 2). By week 48, the median number 
of erosions was 0 in both arms and the 90th percentile did not 
differ between ETN+MTX (0.38) and MTX- TT (0.78) (see 
online supplementary table S24 and figure S5).
Intervention period DMARD changes
Comparable cumulative IM glucocorticoid doses were admin-
istered in each arm (see online supplementary table S25). In 
MTX- TT, 53/60 (88%) escalated to triple therapy by week 24 
(three- quarters by week 12) in line with the 48- week randomised 
treatment protocol. In all patients receiving ETN at week 48, 
ETN was stopped (total 91; 60 and 31 in ETN+MTX and MTX- 
TT, respectively). Four patients (ETN+MTX) withdrawn prior 
to week 48 consented to continued observational follow- up; all 
four were escalated to double/triple csDMARD therapy by week 
48 (see online supplementary table S26).
Observational period DMARD changes
On cessation of ETN (in ETN+MTX arm) at week 48 25/60 
escalated to at least one additional csDMARD, with six on triple 
therapy by week 96. Three patients in ETN+MTX arm were 
commenced on a bDMARD (two adalimumab and one abata-
cept) as per NICE guidelines (DAS28 >5.1) and one patient in 
MTX- TT (ETN) (see online supplementary table S26).
On withdrawal of ETN in the ETN+MTX arm, DAS28- ESR 
remission rate from week 48 to week 96 dropped by only 4% 
(with addition of csDMARD as above; figure 2).
safety
A number of AEs per 100 patient- years in the ETN+MTX and 
MTX- TT arms were 413.6 and 509.6, respectively, most 
frequently infections and gastrointestinal events (numerically 
higher in MTX- TT). A number of SAEs per 100 patient- years 
were 10.6 and 5.9 in ETN+MTX and MTX- TT, respectively. 
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Figure 4 Patient- reported outcomes over time. ESR, erythrocyte sedimentation rate; ETN, etanercept; HAQ- DI, Health Assessment Questionnaire 
Disability Index; MTX, methotrexate; RAQoL, Rheumatoid Arthritis Quality of Life; TT, treat- to- target; VAS, Visual Analogue Scale.
Table 2 Total Grey Scale (GS) and power Doppler (PD) ultrasound scores
Total Gs
Visit
Estimated % Gs >0 Estimated median (95% CI)
difference (95% CI) T value, p valueETn+MTX (n=60) MTX- TT (n=60) ETn+MTX (n=60) MTX- TT (n=60)
Baseline 75 70 3.00 (1.96 to 4.04) 2.00 (0.70 to 3.30)
Week 12 56 69 1.00 (0.48 to 1.52) 2.00 (1.22 to 2.78) 1.00 (0.14 to 1.86) t=2.29, p=0.024
Week 24 60 58 1.00 (0.22 to 1.78) 1.18 (0.02 to 2.34) 0.18 (−1.21 to 1.57) t=0.26, p=0.797
Week 48 53 53 0.96 (0.32 to 1.60) 0.94 (0.21 to 1.67) −0.02 (−0.98 to 0.94) t=−0.04, p=0.967
Total Pd
Visit
Estimated % Pd >0 Estimated 90th percentile* (95% CI)
difference (95% CI) T value, P valueETn+MTX (n=60) MTX- TT (n=60) ETn+MTX (n=60) MTX- TT (n=60)
Baseline 47 45 5.00 (1.93 to 8.07) 4.00 (0.93 to 7.07)
Week 12 15 15 1.00 (−0.80 to 2.80) 3.00 (−0.07 to 6.07) 1.82 (−1.79 to 5.43) t=1.00, p=0.320
Week 24 13 18 1.02 (−1.19 to 3.23) 1.68 (−0.66 to 4.02) 0.42 (−2.77 to 3.61) t=0.26, p=0.795
Week 48 8 13 0.06 (−2.62 to 2.74) 0.70 (−1.13 to 2.53) 0.46 (−2.28 to 3.20) t=0.33, p=0.739
*Median was 0 in both groups at all visits. Unplanned use of 90th percentile instead of median as point of comparison.
ETN, etanercept; MTX, methotrexate; TT, treat- to- target.
Withdrawals due to AE/SAE up to week 48 occurred in six 
subjects (three SAEs, pulmonary embolism (ETN+MTX), pneu-
monia and acute appendicitis (both MTX- TT); and three AEs, 
neutropaenia and palmoplantar pustulosis (both ETN+MTX) 
and general non- specific symptoms (MTX- TT)). Online supple-
mentary table S27 details all AE and SAE.
dIsCussIOn
This study was not designed to demonstrate the standard level 
of superiority with first- line ETN- MTX such as was observed 
in COMET.10 We aimed to validate the post hoc analysis of 
COMET13 that suggested a much larger effect (30%) of ETN- 
MTX compared with MTX- TT in patients at the earliest 
stages of their RA, which we did not confirm in our study. 
A 14% difference was instead observed, which is consistent 
with the smaller, but still clinically relevant, effect reported 
for ERA.10 Escalation to ETN in those that failed to achieve 
remission with MTX- TT at 6 months may not secure a compa-
rable response to first- line ETN, possibly suggesting reduced 
TNFi- responsiveness.
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While remission is the goal in early, new- onset RA1 60% 
receiving MTX- TT did not achieve this by week 48 (comparable 
to other studies that report 30%–60%28–30; and only 50% in 
the ETN+MTX arm, lower than predicted.13 30 A more posi-
tive interpretation, namely, 40% and 50% achieving remission, 
respectively, still highlights what we would consider suboptimal 
rates for the contemporary era. Our study optimised design 
features that could contribute to reduced response including 
ERA defined by symptom as opposed to disease duration and 
all DMARD- naive not MTX- naive5 10 28 30; expedient MTX, 
csDMARD and bDMARD escalation and adjunctive cortico-
steroid use.31 MTX intolerance does not appear to explain the 
findings, with minimal drop- out in both arms (with n=2 AE and 
n=3 non- compliance in MTX- TT and n=4 and 1, respectively, 
ETN+MTX).
Our study eligibility aligned with clinical practice, repre-
senting a real- world population. Half the cohort had at least one 
comorbidity, and 20% at least two. This may have partly driven 
the generally poorer than expected performance32 33; the exact 
mechanisms for which are unclear.
The suboptimal remission rates did not appear to be driven by 
joint- related inflammation; as evidenced by US PD suppressed 
in both arms to <13% with any PD by week 48. GS persisted 
in over half the cohort (in particularly, the wrist), likely indi-
cating normal background GS in joints and fibrotic change. 
Radiographic and US erosion scores were comparable. Pain was 
also effectively suppressed by both strategies. Of note, only 50% 
of patients had PD at baseline despite a minimum of moderate 
DAS28 disease activity Discrepant observations between US 
findings and DAS are well recognised.34–36 Our clinical and US 
findings further highlight the complexities of achieving remis-
sion (see online supplementary figures S6–S7) plot DAS28 
components and different DAS28 definitions for each treatment 
arm to illustrate some of these issues in this cohort).
Remission rate did not improve appreciably with escalation 
to bDMARD at week 24 in the MTX- TT cohort1 (with 60% 
still failing to achieve remission at week 48), and TNFi escala-
tion unable to move this subgroup even to a low disease activity 
state. Planned exploratory analysis suggested 24 weeks expo-
sure of ETN following MTX- TT- IR may be associated with a 
lower remission rate compared with first- line ETN+MTX. In 
comparison, a post hoc exploratory analysis of the Optimal 
Protocol for Treatment Initiation with Methotrexate and 
Adalimumab (OPTIMA) trial6 demonstrated little advantage to 
starting with adalimumab and MTX. To definitively confirm 
our findings would require comparison of strategies in (an as 
of yet undefined) patient population who were all likely to 
fail first- line MTX- TT; (where arguably unethical to include 
MTX- TT as a strategy). Finally, this study did not seek to 
address how to manage new onset RA and first- line TNFi- IR 
at week 24.
The open- label nature of this study is a legitimate source of 
bias (although would be expected to overestimate response). 
However, we sought to capture real- world practice. The use of 
blinded assessors ensured key components of the endpoints were 
free from such bias. Also, the drop- out rate was almost twice that 
anticipated. US of only the dominant hand may partly explain 
the discrepancy between suppression of PD in almost all subjects 
but failure to achieve remission in half the patients. Finally, ETN 
tapering protocol after week 48 would have been desirable; 
however, in England, NICE does not reimburse ETN until in 
high disease activity, forcing immediate cessation. In contrast 
to PRESERVE,37 we observed minimal (4%) drop in remission 
rates, likely attributable to the early, treatment- naïve cohort.
In summary, the VEDERA study did not demonstrate the 
larger than standard effect size (of 30%), which was proposed 
to exist in a previous exploratory subgroup analysis with first- 
line TNFi- MTX in very ERA. These data also highlight a ceiling 
effect in achieving remission in a real life, comorbid ERA cohort. 
The suggestion that expedient addition of ETN to MTX- TT- IR 
may not be as effective in a proportion as in treatment- naïve 
patients requires validation and further investigation.
Patient and public involvement
Independent lay individual from our public and patient advocacy 
group provided input into study design.
Author affiliations
1leeds institute of rheumatic and Musculoskeletal Medicine, University of leeds, 
leeds, UK
2niHr leeds Biomedical research centre, leeds Teaching Hospitals nHs Trust, leeds, 
UK
3central lancashire Moving Well service, lancashire and south cumbria nHs 
Foundation Trust, Preston, UK
4Department of rheumatology, leiden University Medical centre, leiden, The 
netherlands
5centre for Musculoskeletal research, school of Biological sciences, Faculty of 
Biology, Medicine & Health, University of Manchester, Manchester, UK
6niHr Manchester Biomedical research centre, Manchester academic Health 
science centre, Manchester University Foundation Trust, Manchester, UK
Acknowledgements We would like to thank the patients for participating in this 
study. also, the clinical rheumatology staff at leeds Teaching Hospitals nHs Trust 
for identifying patients. Gratitude to laura Horton and Kate smith for performing 
consistent ultrasound and Katherine russell, the principal study research nurse. 
Finally, the trials administration team led by James Goulding and the monitoring 
and source data verification team (led by rebecca leslie and supported by nuria 
navarro- coy and catherine Bruckner) for ensuring complete data integrity.
Contributors The VeDera trial was conceived by MHB and Pe. eMaH was 
principal statistician. eMaH and MHB provided overall responsibility for the research 
methodology and statistical analysis plan. sH was the principal clinical fellow who 
supported MHB to submit the trial ethics and setup. sH, rBD and Kn were the 
clinical research fellows over the trial duration. DvdH oversaw the scoring and 
interpretation of X- ray data, and rJW oversaw ultrasound component of the study. 
MHB drafted the manuscript, with critical input from eMaH and Pe. all authors had 
the opportunity to further revise the manuscript and approved the final version.
Funding Pfizer supported the VeDera study via an investigator sponsored research 
grant ref. Ws1092499.
disclaimer The views expressed are those of the author(s) and not necessarily 
those of the niHr or the Department of Health and social care. Pfizer did not have 
any role in the study design, study delivery, statistical analyses, interpretation of data 
or manuscript preparation. The corresponding author had full access to all the data 
in the study and had final responsibility for the decision to submit the report for 
publication.
Competing interests Pe has undertaken clinical trials and provided expert advice 
to Pfizer, MsD, abbvie, BMs, UcB, roche, novartis, samsung, sandoz and lilly. 
Pe has received consultant fees from BMs, abbVie, Pfizer, MsD, novartis, roche 
and UcB. Pe has received research grants paid to his employer from abbVie, BMs, 
Pfizer, MsD and roche. MHB has provided expert advice and received consultant 
fees from abbVie, Bristol- Myers squibb, eli lilly, eMD serono, Pfizer, roche, sandoz, 
sanofi and UcB and has received research grants paid to her employer from 
Pfizer Bristol- Myers squibb ltd, roche, UcB. DvdH has provided expert advice and 
received consultant fees from abbvie, amgen, astellas, astraZeneca, Bristol- Myers 
squibb, Boehringer ingleheim, celgene, cyxone, Daichii, eisai, eli lilly, Galapagos, 
Gilead, GsK, Janssen, Merck, novartis, Pfizer, regeneron, roche, sanofi, Takeda, 
UcB Pharma.
Patient consent for publication not required.
Ethics approval The national research ethics service (leeds (West) research 
ethics committee) approved the protocol (reference 10/H1307/138); and its 
amendments. The study was conducted in accordance with the principles of the 
Declaration of Helsinki.
Provenance and peer review not commissioned; externally peer reviewed.
data availability statement Data are available on reasonable request. all data 
relevant to the study are included in the article or uploaded as online supplementary 
information. additional data are available on reasonable request.
H
ospital M
edical Library. Protected by copyright.
 o
n
 February 12, 2020 at Assistant Librarian St Jam
es`s
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2019-216539 on 29 January 2020. Downloaded from
 
8 Emery P, et al. Ann Rheum Dis 2020;0:1–8. doi:10.1136/annrheumdis-2019-216539
Early arthritis
Open access This is an open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY- nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. see: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
OrCId ids
Paul emery http:// orcid. org/ 0000- 0002- 7429- 8482
raluca Bianca Dumitru http:// orcid. org/ 0000- 0002- 0833- 4852
Désirée van der Heijde http:// orcid. org/ 0000- 0002- 5781- 158X
Maya H Buch http:// orcid. org/ 0000- 0002- 8962- 5642
RefeRences
 1 smolen Js, landewé r, Bijlsma J, et al. eUlar recommendations for the management 
of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic 
drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
 2 nam Jl, Takase- Minegishi K, ramiro s, et al. efficacy of biological disease- modifying 
antirheumatic drugs: a systematic literature review informing the 2016 update of the 
eUlar recommendations for the management of rheumatoid arthritis. Ann Rheum 
Dis 2017;76:1113–36.
 3 Goekoop- ruiterman YPM, De Vries- Bouwstra JK, allaart cF, et al. clinical and 
radiographic outcomes of four different treatment strategies in patients with early 
rheumatoid arthritis (the best study): a randomized, controlled trial. Arthritis Rheum 
2005;52:3381–90.
 4 nam Jl, Villeneuve e, Hensor eMa, et al. remission induction comparing infliximab 
and high- dose intravenous steroid, followed by treat- to- target: a double- blind, 
randomised, controlled trial in new- onset, treatment- naive, rheumatoid arthritis (the 
idea study). Ann Rheum Dis 2014;73:75–85.
 5 van Vollenhoven rF, ernestam s, Geborek P, et al. addition of infliximab compared 
with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients 
with early rheumatoid arthritis (swefot trial): 1- year results of a randomised trial. 
Lancet 2009;374:459–66.
 6 smolen Js, emery P, Fleischmann r, et al. adjustment of therapy in rheumatoid 
arthritis on the basis of achievement of stable low disease activity with adalimumab 
plus methotrexate or methotrexate alone: the randomised controlled optima trial. 
Lancet 2014;383:321–32.
 7 Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al. early rheumatoid arthritis treated 
with tocilizumab, methotrexate, or their combination (U- act- early): a multicentre, 
randomised, double- blind, double- dummy, strategy trial. Lancet 2016;388:343–55.
 8 landewé rBM. overdiagnosis and overtreatment in rheumatology: a little caution is 
in order. Ann Rheum Dis 2018;102:annrheumdis-2018-213700–-2016.
 9 nam Jl, Villeneuve e, Hensor eMa, et al. a randomised controlled trial of etanercept 
and methotrexate to induce remission in early inflammatory arthritis: the empire trial. 
Ann Rheum Dis 2014;73:1027–36.
 10 emery P, Breedveld Fc, Hall s, et al. comparison of methotrexate monotherapy with 
a combination of methotrexate and etanercept in active, early, moderate to severe 
rheumatoid arthritis (coMeT): a randomised, double- blind, parallel treatment trial. 
Lancet 2008;372:375–82.
 11 Bejarano V, Quinn M, conaghan PG, et al. effect of the early use of the anti- tumor 
necrosis factor adalimumab on the prevention of job loss in patients with early 
rheumatoid arthritis. Arthritis Rheum 2008;59:1467–74.
 12 schett G, emery P, Tanaka Y, et al. Tapering biologic and conventional DMarD therapy 
in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 
2016;75:1428–37.
 13 emery P, Kvien TK, combe B, et al. combination etanercept and methotrexate 
provides better disease control in very early (<=4 months) versus early rheumatoid 
arthritis (>4 months and <2 years): post hoc analyses from the coMeT study. Ann 
Rheum Dis 2012;71:989–92.
 14 smolen Js, aletaha D. rheumatoid arthritis therapy reappraisal: strategies, 
opportunities and challenges. Nat Rev Rheumatol 2015;11:276–89.
 15 Dumitru rB, Horton s, Hodgson r, et al. a prospective, single- centre, randomised 
study evaluating the clinical, imaging and immunological depth of remission 
achieved by very early versus delayed etanercept in patients with rheumatoid arthritis 
(VeDera). BMC Musculoskelet Disord 2016;17:1–12.
 16 aletaha D, neogi T, silman aJ, et al. 2010 rheumatoid arthritis classification criteria: 
an american college of rheumatology/european league against rheumatism 
collaborative initiative. Ann Rheum Dis 2010;69:1580–8.
 17 nice. Technology appraisal guidance adalimumab, etanercept, inflfliximab, 
certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis 
not previously treated with DMarDs or after conventional DMarDs only have failed, 
2016. available:  nice. org. uk/ guidance/ ta375
 18 Fransen J, van riel PlcM. The disease activity score and the eUlar response criteria. 
Clin Exp Rheumatol 2005;23:s93–9.
 19 aletaha D, smolen Js. The simplified disease activity index (sDai) and clinical disease 
activity index (cDai) to monitor patients in standard clinical care. Best Practice Res 
Research Rheumatol 2007;21:663–75.
 20 Felson DT, anderson JJ, Boers M, et al. american college of rheumatology. preliminary 
definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
 21 Felson DT, smolen Js, Wells G, et al. american college of rheumatology/european 
league against rheumatism provisional definition of remission in rheumatoid arthritis 
for clinical trials. Ann Rheum 2011;63:573–86.
 22 Fries JF, spitz P, Kraines rG, et al. Measurement of patient outcome in arthritis. 
Arthritis Rheum 1980;23:137–45.
 23 euroQol Group. euroQol- a new facility for the measurement of health- related quality 
of life. Health Policy 1990;16:199–208.
 24 Whalley D, McKenna sP, de Jong Z, et al. Quality of life in rheumatoid arthritis. Br J 
Rheumatol 1997;36:884–8.
 25 Brown aK, Quinn Ma, Karim Z, et al. Presence of significant synovitis in rheumatoid 
arthritis patients with disease- modifying antirheumatic drug–induced clinical 
remission: evidence from an imaging study may explain structural progression. 
Arthritis Rheum 2006;54:3761–73.
 26 Pincus T, callahan lF, Fuchs Ha, et al. Quantitative analysis of hand radiographs 
in rheumatoid arthritis: time course of radiographic changes, relation to joint 
examination measures, and comparison of different scoring methods. J Rheumatol 
1995;22:1983–9.
 27 Felson DT, smolen Js, Wells G, et al. american college of rheumatology/european 
league against rheumatism provisional definition of remission in rheumatoid arthritis 
for clinical trials. Arthritis Rheum 2011;63:573–86.
 28 emery P, Bingham co, Burmester Gr, et al. certolizumab pegol in combination 
with dose- optimised methotrexate in DMarD- naïve patients with early, active 
rheumatoid arthritis with poor prognostic factors: 1- year results from c- earlY, 
a randomised, double- blind, placebo- controlled phase iii study. Ann Rheum Dis 
2017;76:96–104.
 29 atsumi T, Tanaka Y, Yamamoto K, et al. clinical benefit of 1- year certolizumab 
pegol (cZP) add- on therapy to methotrexate treatment in patients with early 
rheumatoid arthritis was observed following cZP discontinuation: 2- year 
results of the c- oPera study, a phase iii randomised trial. Ann Rheum Dis 
2017;76:1348–56.
 30 emery P, Hammoudeh M, FitzGerald o, et al. sustained remission with etanercept 
tapering in early rheumatoid arthritis. N Engl J Med 2014;371:1781–92.
 31 Detert J, Bastian H, listing J, et al. induction therapy with adalimumab plus 
methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 
versus methotrexate therapy alone for DMarD- naïve patients with early rheumatoid 
arthritis: hit hard, an investigator- initiated study. Ann Rheum Dis 2013;72:844–50.
 32 radner H, Yoshida K, Frits M, et al. The impact of multimorbidity status on treatment 
response in rheumatoid arthritis patients initiating disease- modifying anti- rheumatic 
drugs. Rheumatology 2015;54:2076–84.
 33 Hitchon ca, Boire G, Haraoui B, et al. self- reported comorbidity is common in 
early inflammatory arthritis and associated with poorer function and worse arthritis 
disease outcomes: results from the canadian early arthritis cohort. Rheumatology 
2016;55:1751–62.
 34 Brown aK, conaghan PG, Karim Z, et al. an explanation for the apparent dissociation 
between clinical remission and continued structural deterioration in rheumatoid 
arthritis. Arthritis Rheum 2008;58:2958–67.
 35 Horton sc, Tan al, Freeston Je, et al. Discordance between the predictors of clinical 
and imaging remission in patients with early rheumatoid arthritis in clinical practice: 
implications for the use of ultrasound within a treatment- to- target strategy. 
Rheumatology 2016;55:1177–87.
 36 Hensor eMa, McKeigue P, ling sF, et al. Validity of a two- component imaging- derived 
disease activity score for improved assessment of synovitis in early rheumatoid 
arthritis. Rheumatology 2019;58:1400–9.
 37 smolen Js, nash P, Durez P, et al. Maintenance, reduction, or withdrawal of 
etanercept after treatment with etanercept and methotrexate in patients with 
moderate rheumatoid arthritis (preserve): a randomised controlled trial. Lancet 
2013;381:918–29.
H
ospital M
edical Library. Protected by copyright.
 o
n
 February 12, 2020 at Assistant Librarian St Jam
es`s
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2019-216539 on 29 January 2020. Downloaded from
 
Online supplementary file 
Methods 
Statistical analysis 
Analysis populations 
Efficacy analyses were conducted in the full analysis set, meeting the requirements of the intention-
to-treat principle. The main analysis of the primary endpoint was supplemented by a sensitivity 
analysis restricted to the per protocol population that comprised all patients in the full analysis set 
with primary endpoint data available and no major protocol violations. Safety analyses were 
conducted in the safety population. See supplementary table S1 for details of each analysis 
population.  
Primary outcome 
The primary analysis was conducted using a Pearson’s Chi-square test. The point estimate and 95% 
confidence interval for the odds of achieving clinical remission is reported. 
A number of sensitivity analyses of the primary outcome were conducted. These consisted of 
available case analysis, best case (response assumed if missing for reasons other than lack of 
efficacy) analysis, worst case (non-response assumed if missing for reasons other than lack of 
efficacy) analysis. We also carried forward the last available on-treatment observation. Additional 
sensitivity analyses made different assumptions about the missing data in each treatment arm: we 
assumed all patients with missing data in the early ETN arm would not have achieved remission, 
while all such patients in the delayed ETN would have achieved remission (designated ‘near split’ 
imputation) or vice versa (designated ‘far split’ imputation). These were designed to test the impacts 
of the most extreme possible deviations from the missing at random assumption required for 
multiple imputation. In addition, the primary analysis was repeated in the per protocol set. 
Secondary outcomes 
Proportions of patients achieving remission, ACR or EULAR response at 96 weeks were compared 
between groups using Pearson’s Chi-squared tests.  Changes in continuous variables over time were 
compared between groups using a linear multilevel modelling approach, mirroring the mixed 
between-within ANOVA model but with less restrictive assumptions about covariance structure. 
Optimal covariance pattern was identified using Akaike Information Criterion (AIC) values after 
inspection of correlations between repeated observations. An autoregressive structure was found to 
be optimal. Robust standard errors were used to address minor deviations from normality in the 
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residuals. Following an overall test of a significant difference between the groups over time, 
comparisons were then made between groups at each time-point. Severely skewed variables were 
analysed using quantile regression; this was required for the ultrasound variables and total Sharp 
score which were heavily right-skewed. The analysis plan specified that median regression would be 
used; however, because of the high prevalence of zero scores for power Doppler and erosion, 
differences between groups at the 90th percentile have been presented instead. 
Time to sustained remission was compared between groups using logrank tests. 
The Holm correction (modified Bonferroni) was used on a family-wise basis to control for multiple 
comparisons of secondary outcomes. This set the critical P-value for testing significance at the 5% 
level to p<0.00088. The correction included secondary outcomes but excluded exploratory 
outcomes; by definition, exploratory analyses are considered hypothesis generating rather than 
confirmatory. 
All analyses have been conducted in Stata v15. 
Rasch analysis of Patient Reported Outcomes 
Quasi-interval-scaled scores were obtained for HAQ-DI, RAQoL and RAWIS using analysis of fit to the 
Rasch model. For HAQ scores, scores were converted using a published conversion table. For RAQoL 
and RAWIS, analysis in RUMM2030 was used to test for overall fit to the model, evidence of local 
dependency, differential item functioning by age, sex and timepoint, multidimensionality and 
targeting. After adopting a testlet approach, both scales were found to fit the model with no 
evidence of specific issues of misfit, although targeting was relatively poor at post-baseline visits as 
many patients’ scores were at the minimum possible. Having demonstrated absence of differential 
item functioning by timepoint, estimates in the full dataset were anchored to the solution obtained 
at baseline, where targeting was best (and threshold estimates were therefore most accurate). 
Other planned analyses 
Proportions of patients in each arm requiring escalation of therapy to triple therapy and to biologic 
therapy have been summarised descriptively, as has cumulative IM steroid dose up to week 48. 
Comparisons have been made between the response in the early ETN group over the first 24 weeks, 
and the response in the delayed ETN group over the 24-48 period in those who were escalated to 
etanercept at week 24. 
Unplanned analyses 
To illustrate trends in disease activity, mean DAS28-ESR (95% CI) has been plotted over time in each 
group; mean (SD) DAS28-ESR and change in DAS28-ESR has been tabulated at each of the primary 
and secondary time-points.  
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Because all medians were 0 at all time-points in both groups for US power Doppler and erosion 
scores, quantile regression analysis has been performed in which the 90th percentile is the target 
rather than the (pre-specified) median (50th percentile). 
Area under the curve DAS28-ESR has been calculated during the first 48 weeks and over the whole 
96 weeks of the trial. To calculate this, values obtained at 12-weekly intervals were used. 
In response to recent interest in sustained remission, and alternative definitions of remission, with 
respect to predicting successful cessation of biologic therapy, sustained remission (defined as 
remission at both the current and immediately preceding 12-weekly visit) has been calculated at 
weeks 48 and 96 for DAS28 remission (<2.6), deep DAS28-ESR remission (<1.98), Boolean remission 
(tender joint count<=1 & swollen joint count<=1 & CRP<=10 mg/L & patient disease activity VAS 
<=10mm). For calculation of Boolean remission, 28 joint counts were augmented with assessments 
of the ankles and MTPs, as recommended by the developers of the criteria. Odds ratios and 95% 
confidence intervals have been calculated for the odds of achieving DAS28-ESR remission at week 96 
according to the level of remission at week 48, in the group as a whole (irrespective of treatment 
group). The odds of achieving DAS28-ESR remission at week 96 according to DAS28 remission status 
at week 48 have also been calculated within each treatment arm, and within a subgroup of MTX-TT; 
MTX-TTb (delayed ETN arm) defined by ETN escalation status at week 24. 
Handling of missing data 
Missing values at baseline were imputed using screening values, where available. 
For response variables (including the primary outcome) patients who discontinued study medication 
for lack of efficacy were considered non-responders from that point forward.  
In all other instances, missing data were addressed using multiple imputation by chained equations. 
Predictive mean matching (10 nearest neighbours) was used to impute all variables. We imputed 50 
datasets and combined the results of our analyses according to Rubin’s rules. 
Imputation models were as follows: 
For all disease activity outcomes that included 28 joint counts: 
[SJC28, TJC28, lnCRP, lnESR, physician global VAS, pain VAS, disease activity VAS, early morning 
stiffness and HAQ-DI] at 0, 12, 24, 36*, 48, 72 & 96 weeks, age at baseline, sex, symptom duration, 
treatment group and whether or not the patient was escalated to etanercept at week 24 
*Excluding HAQ-DI which was not collected at week 36 
For all disease activity outcomes that included 44 swollen joint count and RAI: 
[SJC44, RAI, lnCRP, lnESR, physician global VAS, pain VAS, disease activity VAS, early morning 
stiffness and HAQ-DI] at 0, 12, 24, 36*, 48, 72 & 96 weeks, age at baseline, sex, symptom duration, 
treatment group and whether or not the patient was escalated to etanercept at week 24 
Supplementary material Ann Rheum Dis
 doi: 10.1136/annrheumdis-2019-216539–8.:10 2020;Ann Rheum Dis, et al. Emery P
*Excluding HAQ-DI which was not collected at week 36 
For all patient-reported outcomes: 
[HAQ-DI, RAQoL, EQ5D, RAWIS, DAS28-ESR, disease activity VAS, early morning stiffness] at 0, 12, 24, 
48, 72 & 96 weeks, age at baseline, sex, symptom duration, whether or not the patient was in paid 
employment at baseline (relevant for RAWIS), DAS28-ESR, treatment group and whether or not the 
patient was escalated to etanercept at week 24 
For all imaging outcomes: 
[lnCRP, early morning stiffness, SJC28, TJC28, lnESR, disease activity VAS, physician global VAS, total 
GS score, total PD score, total erosion score, total tenosynovitis score, total osteophyte score] at 
weeks 0, 12, 24 & 48, [lnCRP, SJC28, TJC28, lnESR, disease activity VAS] at week 36, [total modified 
Sharp score] at weeks 0, 48 & 96, age at baseline, sex, symptom duration, treatment group and 
whether or not the patient was escalated to etanercept at week 24 
Missing visit patterns 
Visits that occurred more than 2 weeks from the scheduled date were considered to be missing and 
data were imputed as detailed above. This was necessary for six visits in six patients. Two were at 
the primary endpoint 48 weeks, three were at 24 weeks, one was at week 96.  
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Results 
Table S1: Analysis populations, screening criteria and per protocol exclusions 
Analysis population All ETN+MTX MTX-TT 
Screening population       177        60        60 
Full analysis set       120        60        60 
Safety population       120        60        60 
Per protocol efficacy 84/120 
(70%) 
45/60 
(75%) 
39/60 
(65%) 
In/exclusion criteria met 
(in screening population) 
Failed 
(n=57) 
ETN+MTX 
(n=60) 
MTX-TT 
(n=60) 
IN: Patient aged 18-80 57 60 60 
IN: 2010 ACR/EULAR criteria 57 60 60 
IN: Symptom onset <12months 54 60 60 
IN: Active disease 49 60 60 
IN: ACPA or PD positive 56 60 60 
IN: No previous DMARDs 57 60 60 
IN: Use contraception 57 60 60 
EX: Corticosteroid IA/IM 0 0 0 
EX: Oral steroid use 1 0 0 
EX: NSAID use or change 2 0 0 
EX: Imaging 19 0 0 
EX: Pregnant/breastfeeding 0 0 0 
EX: Other contraindications* 16 1 0 
EX: Medical history 7 0 0 
EX: Planned surgery 0 0 0 
Reason for exclusion from per protocol efficacy population  
(in full analysis set) 
All 
(n=120) 
ETN+MTX 
(n=60) 
MTX-TT 
(n=60) 
Received prohibited concomitant medications 4 0 4 
Did not meet inclusion criteria (bar contraception) or met 
exclusion criteria (bar safety-related criteria) 
7 4 3 
Study treatment(s) was/were paused for >28 days 1 0 1 
Did not receive randomised treatment** 2 0 2 
Had >1 visit (up to week 48) outside the 7 day window 3 2 1 
Withdrew from study treatment for any reason 16 8 8 
Did not have primary endpoint data available 3 1 2 
*The patient in ETN+MTX who met exclusion criteria for other contraindications was randomised in error before being discovered to 
have a positive quantiferon test; they were withdrawn after 1 dose of ETN 
**Two patients in the delayed ETN group were not fully escalated to ETN despite being eligible; one declined, another felt unwell after 
1 dose and discontinued 
Table S2: Primary outcome DAS28-ESR remission (<2.6) 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  39%  17% 3.18 (1.35, 7.50) Chi-sq=7.0 p=0.008 
Week 24  38%  33% 1.25 (0.58, 2.70) Chi-sq=0.3 p=0.565 
Week 48  52%  38% 1.73 (0.81, 3.70) Chi-sq=2.0 p=0.160 
Week 96  47%  42% 1.20 (0.56, 2.60) Chi-sq=0.2 p=0.641 
Proportions estimated following multiple imputation. CI=confidence interval 
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Table S3: Primary outcome DAS28-ESR remission (<2.6) at 48 weeks - sensitivity analyses 
Population: Full analysis set (with exception of per protocol analysis, conducted in per protocol set) 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Best case   63% (38/60)   50% (30/60) 1.73 (0.83, 3.58) Chi-sq=2.2 p=0.140 
Worst case   50% (30/60)   33% (20/60) 2.00 (0.96, 4.18) Chi-sq=3.4 p=0.063 
Split: near   50% (30/60)   50% (30/60) 1.00 (0.49, 2.05) Chi-sq=0.0 p=1.000 
Split: far   63% (38/60)   33% (20/60) 3.45 (1.63, 7.32) Chi-sq=11.0 p=0.001 
LOCF   52% (31/60)   35% (21/60) 1.99 (0.95, 4.13) Chi-sq=3.4 p=0.065 
Complete case   58% (30/52)   40% (20/50) 2.05 (0.93, 4.50) Chi-sq=3.2 p=0.073 
Per protocol   58% (26/45)   44% (17/39) 1.77 (0.74, 4.21) Chi-sq=1.7 p=0.194 
Best case imputation: remission assumed if missing. Worst case imputation: non-remission assumed if missing. Split imputation: if 'near', 
non-remission assumed for ETN+MTX, remission for MTX-TT. If 'far': remission assumed for ETN+MTX, non-remission for MTX-TT. 
CI=confidence interval; LOCF=last on-treatment observation carried forward 
Table S4: Secondary outcome DAS28-CRP(<2.6) 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  53%  32% 2.46 (1.17, 5.20)  
Week 24  54%  48% 1.27 (0.60, 2.67)  
Week 48  75%  64% 1.70 (0.74, 3.87)  
Week 96  61%  59% 1.09 (0.49, 2.41) Chi-sq=0.0 p=0.837 
Proportions estimated following multiple imputation. CI=confidence interval 
Table S5: Secondary outcome DAS44-ESR remission (<1.6) 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  31%  13% 2.86 (1.13, 7.23)  
Week 24  40%  30% 1.57 (0.72, 3.43)  
Week 48  54%  39% 1.86 (0.87, 4.00)  
Week 96  46%  44% 1.07 (0.50, 2.32) Chi-sq=0.0 p=0.858 
Proportions estimated following multiple imputation. CI=confidence interval 
Table S6: Secondary outcome DAS44-CRP remission (<1.6) 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  47%  27% 2.46 (1.14, 5.33)  
Week 24  47%  34% 1.74 (0.80, 3.79)  
Week 48  61%  53% 1.38 (0.65, 2.94)  
Week 96  51%  51% 1.03 (0.47, 2.23) Chi-sq=0.0 p=0.946 
Proportions estimated following multiple imputation. CI=confidence interval 
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Table S7: Table of DAS scores and changes at each visit (unplanned analysis) 
Population: Full analysis set 
Outcome Mean score at visit (SD) Mean change from baseline (SD) 
 ETN+MTX (n=60) MTX-TT (n=60) ETN+MTX (n=60) MTX-TT (n=60) 
DAS28-ESR week 12 3.06 (1.16) 3.82 (1.23) -2.71 (1.40) -1.74 (1.36) 
week 24 3.15 (1.50) 3.42 (1.37) -2.62 (1.75) -2.14 (1.36) 
week 48 2.69 (1.19) 2.90 (1.07) -3.08 (1.46) -2.65 (1.45) 
week 96 2.69 (1.29) 2.92 (1.24) -3.08 (1.67) -2.64 (1.72) 
DAS28-CRP week 12 2.64 (1.20) 3.24 (1.24) -2.57 (1.38) -1.67 (1.33) 
week 24 2.76 (1.35) 2.96 (1.34) -2.46 (1.67) -1.94 (1.37) 
week 48 2.24 (1.16) 2.39 (0.90) -2.98 (1.47) -2.52 (1.43) 
week 96 2.45 (1.05) 2.44 (1.07) -2.76 (1.51) -2.46 (1.66) 
DAS44-ESR week 12 1.91 (0.80) 2.44 (0.83) -1.81 (1.00) -1.21 (0.93) 
week 24 1.99 (1.05) 2.21 (0.93) -1.73 (1.23) -1.45 (0.97) 
week 48 1.61 (0.84) 1.87 (0.74) -2.11 (1.05) -1.78 (0.98) 
week 96 1.69 (0.93) 1.81 (0.85) -2.02 (1.14) -1.84 (1.14) 
DAS44-CRP week 12 1.71 (0.82) 2.17 (0.84) -1.75 (1.00) -1.18 (0.92) 
week 24 1.80 (0.98) 2.00 (0.92) -1.65 (1.20) -1.34 (0.97) 
week 48 1.40 (0.84) 1.63 (0.69) -2.06 (1.06) -1.71 (0.98) 
week 96 1.58 (0.84) 1.59 (0.81) -1.88 (1.08) -1.76 (1.15) 
Means and SDs estimated following multiple imputation. SD=Standard deviation 
Table S8: Proportion in DAS28ESR remission or LDA (DAS28ESR<=3.2) (unplanned analysis) 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) 
Week 12  57%  37% 2.27 (1.09, 4.75) 
Week 24  62%  54% 1.42 (0.66, 3.03) 
Week 48  72%  62% 1.59 (0.70, 3.59) 
Week 96  65%  61% 1.17 (0.53, 2.59) 
CI=confidence interval; ETN=etanercept; MTX=methotrexate; TT=treat-to-target 
Table S9: Proportion in ACR/EULAR Boolean remission (unplanned analysis) 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) 
Week 12  20%  13% 1.59 (0.59, 4.25) 
Week 24  17%  12% 1.54 (0.54, 4.40) 
Week 48  29%  23% 1.37 (0.59, 3.17) 
Week 96  29%  26% 1.14 (0.50, 2.62) 
CI=confidence interval; ETN=etanercept; MTX=methotrexate; TT=treat-to-target 
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Table S10: Secondary outcome time to sustained remission 
Population: Full analysis set 
Sustained remission Proportion of patients Survival time 25th percentile Logrank chi-square, P value 
All (n=120) ETN+MTX (n=60) MTX-TT (n=60) ETN+MTX (n=60) MTX-TT (n=60) 
DAS28-ESR   34% (41/120)   42% (25/60)   27% (16/60)   24   36 Chi-sq=4.46 p=0.035 
DAS28-CRP   54% (65/120)   57% (34/60)   52% (31/60)   13   24 Chi-sq=2.06 p=0.151 
DAS44-ESR   33% (40/120)   38% (23/60)   28% (17/60)   24   36 Chi-sq=2.48 p=0.115 
DAS44-CRP   46% (55/120)   48% (29/60)   43% (26/60)   13   24 Chi-sq=1.44 p=0.230 
SDAI   26% (31/120)   33% (20/60)   18% (11/60)   24    - Chi-sq=4.38 p=0.036 
CDAI   28% (33/120)   33% (20/60)   22% (13/60)   24    - Chi-sq=3.07 p=0.080 
Note that because fewer than 50% of patients achieved sustained remission for the majority of remission definitions, medians and 75th percentiles could not be calculated for survival time; only the 25th percentiles 
are presented, where it was possible to calculate these. CRP=C-reactive protein; ESR=erythrocyte sedimentation rate. 
Table S11: Secondary outcome EULAR moderate or good response 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  92%  75% 3.59 (1.21, 10.66)  
Week 24  88%  86% 1.18 (0.37, 3.77)  
Week 48  94%  89% 1.88 (0.43, 8.18)  
Week 96  94%  87% 2.39 (0.58, 9.82) Chi-sq=1.5 p=0.226 
Proportions estimated following multiple imputation. CI=confidence interval 
Table S12: Secondary outcome EULAR good response 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  55%  33% 2.46 (1.17, 5.17)  
Week 24  61%  49% 1.63 (0.77, 3.46)  
Week 48  70%  61% 1.48 (0.66, 3.31)  
Week 96  63%  61% 1.09 (0.50, 2.39) Chi-sq=0.0 p=0.832 
Proportions estimated following multiple imputation. CI=confidence interval 
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Table S13: Secondary outcome ACR20 response 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  75%  55% 2.45 (1.10, 5.46)  
Week 24  69%  67% 1.13 (0.50, 2.54)  
Week 48  83%  73% 1.79 (0.69, 4.60)  
Week 96  77%  72% 1.28 (0.52, 3.16) Chi-sq=0.3 p=0.591 
Proportions estimated following multiple imputation. CI=confidence interval 
Table S14: Secondary outcome ACR50 response 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  66%  36% 3.46 (1.60, 7.50)  
Week 24  53%  47% 1.29 (0.60, 2.76)  
Week 48  69%  56% 1.78 (0.81, 3.92)  
Week 96  64%  55% 1.45 (0.65, 3.21) Chi-sq=0.8 p=0.362 
Proportions estimated following multiple imputation. CI=confidence interval 
Table S15: Secondary outcome ACR70 response 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  36%  21% 2.03 (0.88, 4.67)  
Week 24  42%  28% 1.90 (0.85, 4.22)  
Week 48  58%  44% 1.76 (0.82, 3.75)  
Week 96  50%  42% 1.40 (0.64, 3.07) Chi-sq=0.7 p=0.397 
Proportions estimated following multiple imputation. CI=confidence interval 
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Table S16: Secondary outcome HAQ-DI score 
Population: Full analysis set 
Visit Mean change (95% CI) Difference (95% CI) T value, P value Overall F value, P value 
ETN+MTX (n=60) MTX-TT (n=60) 
Week 12 -0.60 (-0.70, -0.50) -0.41 (-0.51, -0.32) 0.19 (0.04, 0.33) t=2.57, p=0.010 F=1.79, p=0.148 
Week 24 -0.59 (-0.71, -0.47) -0.48 (-0.61, -0.36) 0.11 (-0.07, 0.28) t=1.19, p=0.233  
Week 48 -0.65 (-0.77, -0.53) -0.62 (-0.74, -0.50) 0.03 (-0.14, 0.20) t=0.35, p=0.730  
Week 96 -0.63 (-0.75, -0.51) -0.66 (-0.79, -0.52) -0.02 (-0.20, 0.16) t=-0.26, p=0.797  
Means estimated following multiple imputation. CI=Confidence interval; HAQ-DI=Health assessment questionnaire disability index 
Table S17: Secondary outcome HAQ-DI normalisation (HAQ-DI<=0.5) 
Population: Full analysis set 
Visit ETN+MTX (n=60) MTX-TT (n=60) Odds ratio (95% CI) Chi-square, P value 
Week 12  56%  48% 1.36 (0.66, 2.80)  
Week 24  59%  56% 1.13 (0.53, 2.39)  
Week 48  63%  65% 0.93 (0.43, 2.05)  
Week 96  65%  72% 0.72 (0.31, 1.66) Chi-sq=0.6 p=0.442 
Proportions estimated following multiple imputation. CI=confidence interval 
Table S18: Secondary outcome EQ5D-3L 
Population: Full analysis set 
Visit Mean change (95% CI) Difference (95% CI) T value, P value Overall F value, P value 
ETN+MTX (n=60) MTX-TT (n=60) 
Week 12 0.30 (0.24, 0.35) 0.19 (0.11, 0.26) -0.11 (-0.20, -0.02) t=-2.46, p=0.014 F=0.40, p=0.751 
Week 24 0.32 (0.27, 0.36) 0.22 (0.15, 0.29) -0.10 (-0.17, -0.02) t=-2.58, p=0.010  
Week 48 0.33 (0.27, 0.40) 0.27 (0.20, 0.35) -0.06 (-0.15, 0.03) t=-1.39, p=0.165  
Week 96 0.36 (0.31, 0.41) 0.29 (0.22, 0.36) -0.06 (-0.14, 0.02) t=-1.58, p=0.114  
Means estimated following multiple imputation. CI=confidence interval ; EQ5D-3L=Euroqol health index (5 dimensions 3 levels)  
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Table S19: Secondary outcome pain visual analogue scale (mm) 
Population: Full analysis set 
Visit Mean change (95% CI) Difference (95% CI) T value, P value Overall F value, P value 
ETN+MTX (n=60) MTX-TT (n=60) 
Week 12 -30.52 (-36.44, -24.60) -21.51 (-27.82, -15.20) 9.01 (0.30, 17.73) t=2.03, p=0.043 F=1.76, p=0.152 
Week 24 -25.42 (-32.29, -18.55) -24.18 (-30.49, -17.88) 1.24 (-8.02, 10.50) t=0.26, p=0.793  
Week 48 -32.77 (-38.03, -27.51) -32.84 (-38.62, -27.07) -0.07 (-7.89, 7.75) t=-0.02, p=0.986  
Week 96 -32.79 (-38.45, -27.13) -26.47 (-33.66, -19.27) 6.32 (-2.85, 15.50) t=1.35, p=0.177  
Means estimated following multiple imputation. CI=Confidence interval 
Table S20: Secondary outcome disease activity visual analogue scale (mm) 
Population: Full analysis set 
Visit Mean change (95% CI) Difference (95% CI) T value, P value Overall F value, P value 
ETN+MTX (n=60) MTX-TT (n=60) 
Week 12 -31.36 (-37.20, -25.52) -23.39 (-29.61, -17.17) 7.97 (-0.58, 16.52) t=1.83, p=0.068 F=0.89, p=0.447 
Week 24 -28.92 (-35.15, -22.69) -25.55 (-32.21, -18.90) 3.37 (-5.80, 12.53) t=0.72, p=0.472  
Week 48 -35.37 (-40.87, -29.87) -34.86 (-40.80, -28.92) 0.51 (-7.64, 8.66) t=0.12, p=0.902  
Week 96 -33.88 (-39.91, -27.85) -27.67 (-34.63, -20.71) 6.21 (-3.00, 15.42) t=1.32, p=0.186  
Means estimated following multiple imputation. CI=Confidence interval 
Table S21: Secondary outcome Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire 
Population: Full analysis set 
Visit Mean change (95% CI) Difference (95% CI) T value, P value Overall F value, P value 
ETN+MTX (n=60) MTX-TT (n=60) 
Week 12 -7.78 (-9.35, -6.22) -4.79 (-6.33, -3.25) 2.99 (0.79, 5.19) t=2.67, p=0.008 F=2.30, p=0.075 
Week 24 -7.43 (-9.15, -5.71) -6.31 (-7.96, -4.65) 1.12 (-1.27, 3.51) t=0.92, p=0.358  
Week 48 -8.36 (-10.28, -6.43) -7.90 (-9.77, -6.02) 0.46 (-2.23, 3.15) t=0.34, p=0.737  
Week 96 -8.21 (-10.13, -6.29) -8.25 (-10.16, -6.34) -0.04 (-2.74, 2.66) t=-0.03, p=0.978  
Means estimated following multiple imputation. CI=Confidence interval 
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Table S22: Secondary outcome Rheumatoid Arthritis Work Instability Scale (RAWIS) 
Population: Full analysis set (subset*)  
Visit Mean change (95% CI) Difference (95% CI) T value, P value Overall F value, P value 
ETN+MTX (n=49) MTX-TT (n=39) 
Week 12 -7.34 (-9.50, -5.17) -4.32 (-6.62, -2.01) 3.02 (-0.13, 6.17) t=1.88, p=0.060 F=1.09, p=0.354 
Week 24 -7.05 (-9.39, -4.70) -5.87 (-8.21, -3.53) 1.17 (-2.11, 4.45) t=0.70, p=0.483  
Week 48 -7.69 (-10.01, -5.37) -7.50 (-10.14, -4.86) 0.19 (-3.29, 3.68) t=0.11, p=0.914  
Week 96 -7.50 (-9.99, -5.00) -7.47 (-10.34, -4.60) 0.02 (-3.73, 3.77) t=0.01, p=0.990  
Means estimated following multiple imputation. CI=Confidence interval  
*This scale is only validated for use in people who are in paid work therefore this analysis has been restricted to those who reported being in paid work at baseline 
Table S23: Secondary outcome total modified Sharp score (hands and feet) 
Population: Full analysis set 
Visit % TSS>0 Estimated median change (95% CI) Difference* (95% CI) T value, P value 
ETN+MTX (n=60) MTX-TT (n=60) ETN+MTX (n=60) MTX-TT (n=60) 
Week 48 49% 48% 0.20 (-0.34, 0.73) 0.21 (-0.40, 0.81) 0.01 (-0.79, 0.81) t=0.03, p=0.980 
Week 96 54% 57% 0.36 (-0.26, 0.99) 0.60 (-0.11, 1.31) 0.24 (-0.71, 1.19) t=0.50, p=0.621 
Proportions and medians estimated following multiple imputation. CI=Confidence interval; TSS=Total Sharp score 
Table S24: Secondary outcome total ultrasound erosions 
Population: Full analysis set 
Visit Estimated % E>0 Estimated 90th percentile* (95% CI) Difference (95% CI) T value, P value 
ETN+MTX (n=60) MTX-TT (n=60) ETN+MTX (n=60) MTX-TT (n=60) 
Baseline  16%  12% 1.00 (-1.19, 3.19) 1.00 (0.12, 1.88)   
Week 12  14%   9% 1.00 (-0.75, 2.75) 0.00 (-1.32, 1.32) -1.00 (-2.94, 0.94) t=-1.02, p=0.310 
Week 24   9%  11% 0.10 (-2.18, 2.38) 0.48 (-0.79, 1.75) 0.20 (-2.17, 2.57) t=0.17, p=0.867 
Week 48  11%  13% 0.38 (-1.65, 2.41) 0.78 (-0.83, 2.39) 0.02 (-1.91, 1.95) t=0.02, p=0.984 
Proportions and percentiles estimated following multiple imputation. CI=Confidence interval; E=Erosion  
*Median was 0 in both groups at all visits. Unplanned use of 90th percentile instead of median as point of comparison. 
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Table S25: Secondary outcome cumulative intramuscular steroid dose 
Population: Full analysis set 
Cumulative steroid dose All (n=119) ETN+MTX (n=59) MTX-TT (n=60) 
Up to week 48 (uncorrected) 240.0 (240.0, 240.0), 120-720 240.0 (120.0, 240.0), 120-720 240.0 (240.0, 240.0), 120-600 
Up to week 48 (corrected*)  5.0 ( 5.0,  6.2),  2-18  5.0 ( 2.6,  7.5),  2-15  5.0 ( 5.0,  7.4),  2-18 
All results presented as median (binomial 95% confidence interval), range. Note that one patient in ETN+MTX was withdrawn after baseline; this patient has been excluded from this analysis. 
*Per week of follow-up.    
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Table S26: Escalation of disease-modifying anti-rheumatic drugs (DMARDs) 
Population: Full analysis set 
Treatment started Time interval ETN+MTX (n=60) MTX-TT (n=60) 
ETN Before week 12 100% (60) - (0) 
 Weeks 12 to 23 - (0) - (0) 
 Weeks 24 to 47 - (0) 52% (31) 
 At/after week 48 - (0) 2% (1) 
ADA At/after week 48 3% (2) 2% (1) 
ABA At/after week 48 2% (1) - (0) 
>=2 concurrent csDMARDs Before week 12 2% (1) 73% (44) 
 Weeks 12 to 23 2% (1) 15% (9) 
 Weeks 24 to 47 2% (1) 2% (1) 
 At/after week 48 42% (25) 3% (2) 
3 concurrent csDMARDs Before week 12 - (0) 72% (43) 
 Weeks 12 to 23 - (0) 13% (8) 
 Weeks 24 to 47 2% (1) 2% (1) 
 At/after week 48 10% (6) - (0) 
Note that the patients in the ETN+MTX arm who were escalated to double or triple conventional synthetic DMARD therapy 
prior to week 48 had all been withdrawn from study therapy and were being followed-up observationally. Two were 
withdrawn from ETN due to AEs and received double therapy after cessation of ETN, one was an ETN non-responder and 
received triple therapy. ABA=abatacept; ADA=adalimumab; ETN=etanercept  
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Table S27: Adverse event summary 
Population: Safety population 
 All (n=120; 
PY=205.3) 
ETN+MTX (n=60; 
PY=104.2) 
MTX-TT (n=60; 
PY=101.1) 
AE    
Total AE, n 946 431 515 
Unique AE, n 778 360 418 
AE per 100 PY, n 460.8 413.6 509.6 
Patients with >=1 AE, n 118 58 60 
Discontinuation due to AE, % (n)   7% (8/120)   8% (5/60)   5% (3/60) 
AE by category    
Gastrointestinal, n per 100 PY (n) 63.8 (131) 43.2 (45) 85.1 (86) 
General, n per 100 PY (n) 43.8 (90) 45.1 (47) 42.5 (43) 
Infections, n per 100 PY (n) 163.7 (336) 144.9 (151) 183.1 (185) 
Musculoskeletal, n per 100 PY (n) 20.0 (41) 19.2 (20) 20.8 (21) 
Nervous system, n per 100 PY (n) 34.1 (70) 29.7 (31) 38.6 (39) 
Respiratory, n per 100 PY (n) 29.7 (61) 22.1 (23) 37.6 (38) 
Skin, n per 100 PY (n) 29.7 (61) 33.6 (35) 25.7 (26) 
Other, n per 100 PY (n) 76.0 (156) 75.8 (79) 76.2 (77) 
AE severity*    
Mild, n per 100 PY (n) 264.5 (543) 235.1 (245) 294.9 (298) 
Moderate, n per 100 PY (n) 106.7 (219) 101.7 (106) 111.8 (113) 
Severe, n per 100 PY (n)  6.3 (13)  5.8 ( 6)  6.9 ( 7) 
Life-threatening, n per 100 PY (n)  1.5 ( 3)  2.9 ( 3) 0 (0) 
AE by relation to study drug*    
Not related, n per 100 PY (n) 52.1 (107) 51.8 (54) 52.4 (53) 
Unlikely, n per 100 PY (n) 87.2 (179) 72.9 (76) 101.9 (103) 
Possible, n per 100 PY (n) 174.9 (359) 155.4 (162) 194.9 (197) 
Probable, n per 100 PY (n) 58.0 (119) 56.6 (59) 59.4 (60) 
Definite, n per 100 PY (n)  6.3 (13)  8.6 ( 9)  4.0 ( 4) 
SAE    
Total SAE, n 14 9 5 
SAE per 100 PY, n  6.8  8.6  4.9 
Patients with >=1 SAE, n 12 7 5 
PY=Patient years  
*Recurrent AEs counted once at maximum severity/relation reported.  
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Figure S1: DAS28ESR plotted over time within subgroups defined according to DAS28ESR remission (<2.6) status at week 24 
Solid lines indicate ETN+MTX; dashed lines indicate MTX-TT. Green lines indicate those in remission at week 24; red lines indicate those not in remission at 
week 24. In figure S1b the ETN+MTX arm has also been split according to whether patients had DAS28ESR<2.6 (ETN+MTXa) or DAS28ESR>=2.6 (ETN+MTXb) 
at 24 weeks. 
 
Supplementary material Ann Rheum Dis
 doi: 10.1136/annrheumdis-2019-216539–8.:10 2020;Ann Rheum Dis, et al. Emery P
Figure S2: Cumulative probability plot of total van der Heijde-modified Sharp score at baseline and week 48 
Population: Full analysis set (available case only) 
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Figure S3: Cumulative probability plot of ultrasound grey scale score at baseline and week 48 
Population: Full analysis set (available case only) 
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Figure S4: Cumulative probability plot of ultrasound power Doppler score at baseline and week 48 
Population: Full analysis set (available case only) 
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Figure S5: Cumulative probability plot of ultrasound erosion score at baseline and week 48 
Population: Full analysis set (available case only) 
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Figure S6: DAS28 components and early morning stiffness plotted over time (unplanned analysis) 
Population: Full analysis set (available case only) 
Medians in the ETN+MTX and MTX-TT arms plotted over time for a) TJC28 b) SJC28 c) Erythrocyte sedimentation rate (ESR) d) C-reactive protein (CRP) e) 
patient disease activity visual analogue scale (VASDA) f) early morning stiffness. 
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Figure S7: Different DAS28 definitions plotted over time (unplanned analysis) 
Population: Full analysis set (available case only) 
Medians in the ETN+MTX and MTX-TT arms plotted over time for a) DAS28ESR (objective components; [0.28 x sqrtSJC28] + [0.70 x ln(ESR)]) b) DAS28CRP 
(objective components; [0.28 x sqrtSJC28] + [0.36 x ln(CRP+1)] + 0.96) c) DAS28 (subjective components; [0.56 x sqrtTJC28] + [0.014 x patient disease 
activity visual analogue scale]) d) Four component DAS28ESR e) Four component DAS28CRP f) Two component DAS28CRP. 
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